PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-237

  1. 516 Posts.
    lightbulb Created with Sketch. 43
    Not at all, I think it was news to all of us but a quick google showed that study from a year ago. Clearly an issue to keep an eye on for people who they describe as "chronic" users of oral PPS but from my reading the researchers are recommending more informed regular eye exams for long-term users, for users with the condition to look for an alternative treatment, and for new users to be screened for existing eye conditions. It joins a long list of possible side effects, as per all drugs.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.